Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DAV132
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Da Volterra Reports Positive Top-line Results from DAV132 Study
Details : Primary endpoint met: DAV132 was safe for use in hospitalized patients with several comorbidities and concomitant medications.
Product Name : DAV132
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 02, 2020
Lead Product(s) : DAV132
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable